Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Capital Expenditures: 2015-2025

Historic Capital Expenditures for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to $29,000.

  • Intellia Therapeutics' Capital Expenditures fell 97.73% to $29,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 68.59%. This contributed to the annual value of $5.8 million for FY2024, which is 58.68% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Capital Expenditures of $29,000 as of Q3 2025, which was down 87.87% from $239,000 recorded in Q2 2025.
  • Intellia Therapeutics' Capital Expenditures' 5-year high stood at $4.5 million during Q3 2021, with a 5-year trough of $29,000 in Q3 2025.
  • For the 3-year period, Intellia Therapeutics' Capital Expenditures averaged around $1.9 million, with its median value being $1.3 million (2024).
  • Per our database at Business Quant, Intellia Therapeutics' Capital Expenditures soared by 550.14% in 2021 and then plummeted by 97.73% in 2025.
  • Over the past 5 years, Intellia Therapeutics' Capital Expenditures (Quarterly) stood at $2.9 million in 2021, then soared by 36.40% to $3.9 million in 2022, then crashed by 61.15% to $1.5 million in 2023, then slumped by 35.46% to $981,000 in 2024, then plummeted by 97.73% to $29,000 in 2025.
  • Its last three reported values are $29,000 in Q3 2025, $239,000 for Q2 2025, and $735,000 during Q1 2025.